Author of

• 18606

  +

  P3.03 - Poster Session with Presenters Present (ID 473)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18659

    +

    P3.03-053 - Malignant Mesothelioma in Iranian Patients: A Study from National Institute of Tuberculosis and Lung Disease (ID 4481)

    14:30 - 14:30  |  Author(s): K. Khodadad
    • Abstract

    Background:
    Malignant mesothelioma (MM) is a tumour which originated from lung, chest cavity or abdomen.The close link between exposure to asbestos exposure and MM development is evident. The disease remains challenging in terms of diagnosis, staging and treatment. The aim of this study is to assess clinicopathological and outcome data of Iranian MM patients.
    
    Methods:
    This retrospective study with 126 eligible patients was conducted from January 2002 to February 2016 in National Research Institute of tuberculosis and Lung Disease (NRITLD), Tehran, Iran. The patients belonged to different geographical regions of Iran. Efficacy analysis included progression free survival (PFS) as primary end point. All analysis was performed by SPSS version 16.
    
    Results:
    In this study, male/female ratio was of 2.07 (85/41) and mean age of 55.06± 11.03 years (range 25-80). The histologic subtypes were: epithelioid 28.6%,biphasic 7.1%,sarcomatoid 3.2%,Lymphohistiocytic 0.8%, and in 57.9% the subtype was not determined. In 2.4 % of cases defined as desmoplastic mesothelioma variation. Only, 1 patient had abdominal mesothelioma. Stage distribution was: stage I: 38%, stage II: 21.4%, stage III: 7.9% and 32.5% had stage IV. Only, for 12.7 % cases surgery was performed and 92.9 patients had been received chemotherapy. Asbestos exposure was reported in 35.7 %. Table1. Clinico-pathological data in relation to asbestos exposure

    	Exposure Yes No	CI 95%	Odds ratio	P-value
    Age <70 >71	41 4	65 12	0.572-6.2	1.8	0.29
    Stage I,II and III IV	25 20	33 45	0.813-3.57	1.705	0.156
    Histologic subtype Epitheliod Other subtypes	31 14	48 30	0.635-3.015	1.384	0.413
    Sex Female Male	10 35	31 47	0.188-1	0.433	0.047*
    Response to treatment CR , PR or SD Progressive disease	29 15	50 20	0.344-1.7	0.733	0.534

    * significant P value. Median of PFS was 8.6±1.08 months (CI 95%: 6.5-10.6 months). PFS was mildly longer in patents without asbestos exposure more than the other group but was not statistically significant between patents who had history of to asbestos exposure and who did not.( 8.16 vs 10.6, P=0.880)
    
    Conclusion:
    In our study, 35.7% patients had asbestos exposure and can be described by the long latency period of the tumor. In order to improve the efficacy of MM patients, early diagnosis and effective treatment strategies will be highly expected to develop.